CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
CTLA-4 is a critical inhibitory “checkpoint” molecule of immune activation. Several recent reports have described patients with immune dysregulation and lymphoproliferative disease resulting from 2 different genetic diseases that directly or indirectly cause CTLA-4 deficiency. Numerous articles have also been published describing CTLA-4 blockade in cancer immunotherapy and its side effects, which are ultimately the consequence of treatment-induced CTLA-4 deficiency. Here, we review these 2 diseases and CTLA-4 blockade therapy, emphasizing the crucial role of CTLA-4 in immune checkpoint regulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 1×
“This approvalwas the result ofmultiple late-phase clinical trials demonstrating that ipilimumab significantly increased the mean and long-term survival of patients with advanced melanoma.(46,47) Notably, approximately two-thirds of patients treated with ipilimumab experienced immune-related adverse events associated w…”
BackgroundCTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956 · cited 2×
“In mice with complete germ-line deficiency of CTLA-4, unrestrained T-cell expansion causes death at 4 weeks old,(2,3) whereas the loss of CTLA-4 selectively on Treg cells leads to fatal lymphoproliferation by;7 weeks of age.(28) In CHAI patients, compromising a single allele can predispose them to severe infiltrative…”
BackgroundTivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914 · cited 1×
“The essential role of CTLA-4 in lymphocyte homeostasis and tolerance is illustrated by Ctla4 knockout mice, which develop rapidly fatal destructive multiorgan lymphocytic infiltration.(2,3) CTLA4 recessive disease has not yet been reported in humans.”
BackgroundLymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766 · cited 2×
“However, because optimal humoral immunity depends onCD28 signaling andT-cell help, CTLA-4 loss might have been expected to augment antibody levels and B-cell numbers as seen in knockout mouse models.(2,31-33) Instead, patient B-cell numbers and antibody levels progressively decline over time.”
BackgroundTrans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4
Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., et al. (2011) · Science · doi:10.1126/science.1202947 · Cited by 1,860
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415 · cited 1×
“CTLA-4 blockade in melanoma patients also commonly caused skin-related disorders associatedwith increased lymphocytic infiltration and melanocyte apoptosis, which differs from those afflicted with CHAI and LATAIE disease.(46,48) These side effects were reported to be successfully managed with systemic corticosteroids…”
BackgroundZeiser, R., Leveson-Gower, D. B., Zambricki, E. A., Kambham, N., Beilhack, A., Loh, J., Hou, J.-Z., & Negrin, R. S. (2008) · Blood · doi:10.1182/blood-2007-06-094482 · Cited by 402
Cited by
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Immune-related adverse events of checkpoint inhibitors
Ramos-Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suárez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,412
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0013 · Cited by 570
WDFY4 is required for cross-presentation in response to viral and tumor antigens
Theisen, D. J., Davidson, J. T., Briseño, C. G., Gargaro, M., Lauron, E. J., Wang, Q., Desai, P., Durai, V., Bagadia, P., Brickner, J. R., et al. (2018) · Science · doi:10.1126/science.aat5030 · Cited by 346
Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities
Pauken, K. E., Dougan, M., Rose, N. R., Lichtman, A. H., & Sharpe, A. H. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.04.002 · Cited by 280
Metadata
- Authors
- Lo, B., Fritz, J. M., Su, H. C., Uzel, G., Jordan, M. B., & Lenardo, M. J.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2016-08-25
- Volume
- 128
- Issue
- 8
- Pages
- 1037-1042
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2461116874
- Cited by
- 155
- References
- 7
- FWCI
- 9.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency. https://app.cochat.ai/papers/10.1182/blood-2016-04-712612
- The paper
- Lo, B., Fritz, J. M., Su, H. C., Uzel, G., Jordan, M. B., & Lenardo, M. J. (2016). CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency. Blood. https://doi.org/10.1182/blood-2016-04-712612
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.